Search

Your search keyword '"Mohdhar Habib"' showing total 4 results
Start Over Author "Mohdhar Habib" Journal journal of the american college of cardiology
4 results on '"Mohdhar Habib"'

1. STATIN TREATMENT AND RISK OF CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH MYOCARDIAL INFARCTION IN AN INTEGRATED HEALTHCARE SYSTEM

Author

Catherine B McGuiness, Pallavi Rane, Abdelhadi Rifai, Belinda Schludi, Rasha Alkhatib, Yi Li, Yangyang Liu, Mohdhar Habib, Rolin L Wade, and Neal Sawlani

Subjects
medicine.medical_specialty, business.industry, Statin treatment, medicine.disease, Lipid-lowering therapy, Emergency medicine, medicine, cardiovascular diseases, Myocardial infarction, Medical prescription, Cardiology and Cardiovascular Medicine, business, Cardiovascular outcomes, Healthcare system
Abstract

Physician prescription patterns for lipid lowering therapy, particularly high-intensity statins (HIS), and risk of cardiovascular events (CVE) is not well documented in the real-world clinical setting among patients hospitalized with acute myocardial infarction (AMI). We aim to examine the

Published
2020
Full Text
View/download PDF

2. LIPID LOWERING TREATMENT PATTERNS AND RISK OF SUBSEQUENT CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH A RECENT CORONARY REVASCULARIZATION

Author

Sasikiran Nunna, Catherine B McGuiness, Pallavi Rane, Matthew Aaron Cavender, Rolin L. Wade, Mohdhar Habib, and Jason Exter

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Cardiology, medicine, Patient characteristics, Lipid lowering, Cardiology and Cardiovascular Medicine, business, Cardiovascular outcomes, Coronary revascularization, Lipid-lowering therapy
Abstract

We describe patient characteristics, lipid lowering therapy (LLT) use, and risks of subsequent cardiovascular events (CVE) in the 12-months following a coronary revascularization (CR). We identified patients undergoing CR between 01/2014-05/2019 (index period) in the linked IQVIA PharMetrics+/

Published
2020
Full Text
View/download PDF

3. STATIN TREATMENT PATTERNS AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN AN INTEGRATED HEALTHCARE SYSTEM

Author

Pallavi Rane, Yangyang Liu, Belinda Schludi, Neal Sawlani, Rolin L Wade, Catherine B McGuiness, Mohdhar Habib, Abdelhadi Rifai, Yi Li, and Rasha Alkhatib

Subjects
Secondary prevention, medicine.medical_specialty, business.industry, Statin treatment, medicine.disease, Lipid-lowering therapy, medicine, cardiovascular diseases, Myocardial infarction, Medical prescription, Cardiology and Cardiovascular Medicine, Intensive care medicine, business, Healthcare system
Abstract

Lipid lowering therapy, particularly use of high-intensity statins (HIS) is vital for secondary prevention of cardiovascular events, after acute myocardial infarction (AMI). However, physician prescription patterns for HIS are not well documented in the real-world setting in post-AMI patients. We

Published
2020
Full Text
View/download PDF

4. BASELINE CARDIOVASCULAR RISK FOR PATIENTS WITH RECENT MYOCARDIAL INFARCTION PRESCRIBED A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR

Author

Rolin L. Wade, Sasikiran Nunna, Chi-Chang Chen, Pin Xiang, Pallavi Rane, Mohdhar Habib, Xin Wang, Seth J. Baum, and Belinda Schludi

Subjects
medicine.medical_specialty, animal structures, business.industry, fungi, Subtilisin, Proprotein convertase, Risk profile, Endocrinology, Ezetimibe, Internal medicine, medicine, Kexin, lipids (amino acids, peptides, and proteins), In patient, Cardiology and Cardiovascular Medicine, business, Lipoprotein cholesterol, medicine.drug, Recent myocardial infarction
Abstract

Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) antibodies significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients uncontrolled with statins and/or ezetimibe. Here we characterize the baseline cardiovascular risk profile in a subset of patients with recent

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results